anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Systems and methods for monitoring subjects after discharge from a hospital use a dynamic baseline to determine whether a caregiver needs to be notified regarding exacerbation of a medical state of a subject. The subjects are chronic obstructive pulmonary disease (COPD) patients. The dynamic baseline is determined by aggregating (for example averaging) multiple values of a sequence of values for a metric that quantifies one or both of a patient symptom (e.g. the number of overnight apnea occurrences) and/or lung function of a subject (e.g. forced expiratory volume in 1 second). Multiple metrics may be combined to generate the value that is monitored for a subject.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes novel derivatives of arabinofuranosylcytosine of the formula (I)   (Ara-C) where R 1  and R 2  are taken independently from hydrogen atom and C 18 - and C 20 -saturated and monounsaturated acyl groups under condition that R 1  and R 2  both are not hydrogen atom; if R 1  means hydrogen atom then R 2  does not mean eicosenoyl (cis, trans) when R 1  means eicosenoyl (cis, trans), oleoyl, stearoyl, eicosanoyl; if R 1  means eladoyl then R 2  does not mean eicosenoyl (cis, trans), stearoyl, eicosanoyl; if R 1  means oleoyl then R 2  does not mean eicosenoyl (cis, trans), stearoyl; if R 1  means eicosanoyl then R 2  does not mean stearoyl; if R 1  means stearoyl then R 2  does not mean eicosanoyl, oleoyl. Invention describes the use of derivative of Ara-C of the formula (I) for preparing pharmaceutical preparation for treatment of patients with solid tumors and lymphomas. Invention describes also pharmaceutical composition for treatment of patients with solid tumors and lymphomas. EFFECT: new derivatives indicated above, valuable antitumor properties. 12 cl, 21 dwg, 3 ex
Natural disasters pose significant challenges to medical response due to the surge of patients and emergent injuries. Amid such scenarios, where personnel for patient monitoring might be scarce, effective biomarkers are crucial for guiding treatment plans and predicting patient prognosis. We aimed to evaluate the correlation between systemic inflammatory indices and morbidity in earth-quake-induced crush injuries. Additionally, we assessed the potential of these indices as prognostic markers for adverse outcomes. We studied 140 patients with earthquake-related crush injuries (ECR) admitted between February and March 2023 and compared them to 200 healthy controls (CG) chosen using a simple random method. Using the complete blood count data upon admission, we computed and statistically compared indices including NLR (neutrophil lymphocyte ratio), PLR (platelet lymphocyte ratio), MLR (monocyte lymphocyte ratio), SII (systemic immune-inflammatory index), SIRI (systemic inflammatory response index), and PIV (pan-immune inflammation value). Regression analyses determined the prediction of hospitalization duration and dialysis necessity. PLR and MLR upon admission significantly predicted the length of hospital stay. MLR and SIRI were significant predictors for dialysis requirement, with Exp(B) values of 0.306 (p = 0.024) and 1.261 (p = 0.038), respectively. Systemic inflammatory indices can serve as valuable prognostic tools in disaster scenarios. Utilizing these indices can enhance patient management, effectively allocate resources, and potentially save lives in the aftermath of earthquakes.
Vestibular hypofunction characterized by impaired balance and spatial orientation due to the inner ear's vestibular system issues present significant challenges for affected individuals. Gaze stability exercises enhance focus despite head movements while optokinetic exercises improve eye movement control. Both interventions benefit people with vestibular issues aiming to enhance stability, decrease dizziness and improve balance. This study aims to investigate and compare the effects of gaze stability exercises and optokinetic exercises on dizziness, balance, and activities of daily living in patients with vestibular hypofunction.

This randomized clinical trial will occur at Bahawal Victoria Hospital, Bahawalpur within 7 months after the approval of synopsis. The sample size for this trial will be 40 participants. Participants fulfilling the inclusion criteria will be recruited by using the convenience sampling randomly allocated into two groups by computer generator method. 20 participants will be assigned to Group A receiving gaze stability exercises and 20 to the Group B receiving optokinetic exercises, both alongside routine physical therapy. Each group will undergo 5 weekly sessions of treatment for 4 weeks.

The assessment tools include Dizziness Handicap Inventory for dizziness; Mini-BESTest and modified-Clinical Test of Sensory Interaction of Balance for balance assessment while Vestibular Disorders Activities of Daily Living Scale for daily activities. Assessment will be carried out at baseline, 2nd and 4th week. The data will be analyzed using SPSS version 24 for Windows software with the significance level set at p = 0.05. Shapiro-Wilk test will assess data normality. Between group analysis will utilize the Independent t-test for parametric data and Mann-Whitney test for non-parametric data. Within group comparisons will employ repeated measure ANOVA Paired t- test for parametric data and Friedman ANOVA for non-parametric data.
INTRODUCTION: End-stage renal disease is a major risk factor for cardiovascular morbidity and mortality, which can be partially eliminated by kidney transplantation. Systolic heart failure might be considered contraindication for kidney transplant, although some patients demonstrate myocardial recovery post-transplant. We aimed to identify and characterize the phenomenon of reverse myocardial remodeling in kidney transplanted patients.
METHODS: The study is a retrospective cohort of patients undergoing kidney transplants between 2016 and 2019 (n = 604) at Rabin Medical Center. Patients were assessed according to availability of two echocardiographic examinations: pre- and post-kidney transplant. The change in estimated ejection fraction (EF) and possible predictors of myocardial recovery were examined.
RESULTS: Data of 293 patients was available for the final analysis. Eighty-one (28%) patients had a LVEF improvement equal to or above 5%, whereas 36 (12%) patients had a LVEF improvement of 10% or more post-transplantation. Twenty-five patients (8.5%) had moderate or severe systolic heart failure with LVEF reduced to 40% or less at baseline. 13 of them (52%) had a LVEF improvement of ≥5%, and 10 patients (40%) had an improvement of ≥10% in their EF. Cox regression analyses identified female gender as the only independent variable associated with LVEF improvement of at least 10%.
CONCLUSION: Renal transplantation might lead to improved LV systolic function in some patients.
The group of school-aged children from Vietnam who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
Migraine is a common and disabling primary headache disorder and inflammation is a proposed factor in the complex ethiology of the disease. Gasdermin D (GSDMD) is a membrane pore-forming protein acting through the caspase system. End result is cell death caused by leakage of intracellular components to extracellular space which also results in inflammation. Stemming from this knowledge, the potential role of GSDMD in migraine was investigated in this prospective study. This prospective study was conducted between September 2022 to April 2023. 47 patients with migraine were designated as the patient group, whereas 47 healthy volunteers were designated as the control group. Serum GSDMD levels of both groups were compared, with an additional comparison between migraine patients during symptom-free and attack periods. Migraine related characteristics of the patients were also included in the study. Median GSDMD levels of the patient and control group did not reveal a significant difference. Nausea, vomiting and severity of headache were found to be correlated with GSDMD levels in migraine patients. Patients with nausea revealed a higher GSDMD level compared to patients without nausea during both symptom-free and attack periods (p = 0.021 and p = 0.01, respectively). Nausea was correlated to higher GSDMD levels in the patient population during symptom-free period (p = 0.030). The severity of pain was positively correlated with GSDMD levels during the attack period (p < 0.001). Gasdermin family and GSDMD in particular are promising prospects for therapy in a wide spectrum of disorders. Gasdermin proteins are candidates to be the focus for future studies both related to pathogenesis and drug therapy in migraine and varying inflammatory-driven clinical pictures.
Type 2 diabetes (T2DM) is now widely considered a major public health epidemic. T2DM is highly prevalent worldwide, is among the leading causes of death, and is an independent risk factor for dementia and less severe forms of cognitive dysfunction. The investigators are utilizing novel technology to understand the role of variability in glucose on neurocognition and functional status among middle-aged and older adults at risk for diabetes. The central hypothesis is that even before diabetes onset, variability in glucose will be associated with worse cognitive function and lower functional status. Participants will be asked to wear a glucose monitoring device over a 10-day period in their home environment. Assessment of functional status and neurocognitive function, in addition to sociodemographic factors, health habits and mood will also occur over two study visits.
OBJECTIVE: In chronic low back pain (CLBP), the relationship between spinal pathologies and paraspinal muscles fat infiltration remains unclear. This study aims to evaluate the relationship between MRI findings and paraspinal muscles morphology and fat infiltration in CLBP patients by quantitative MRI.
METHODS: All the CLBP patients were enrolled from July 2021 to December 2022 in four medical institutions. The cross-sectional area (CSA) and proton density fat fraction (PDFF) of the multifidus (MF) and erector spinae (ES) muscles at the central level of the L4/5 and L5/S1 intervertebral discs were measured. MRI findings included degenerative lumbar spondylolisthesis (DLS), intervertebral disc degeneration (IVDD), facet arthrosis, disc bulge or herniation, and disease duration. The relationship between MRI findings and the paraspinal muscles PDFF and CSA in CLBP patients was analyzed.
RESULTS: A total of 493 CLBP patients were included in the study (198 females, 295 males), with an average age of 45.68 ± 12.91 years. Our research indicates that the number of MRI findings are correlated with the paraspinal muscles PDFF at the L4/5 level, but is not significant. Moreover, the grading of IVDD is the primary factor influencing the paraspinal muscles PDFF at the L4-S1 level (BES at L4/5=1.845, P < 0.05); DLS was a significant factor affecting the PDFF of MF at the L4/5 level (B = 4.774, P < 0.05). After including age, gender, and Body Mass Index (BMI) as control variables in the multivariable regression analysis, age has a significant positive impact on the paraspinal muscles PDFF at the L4-S1 level, with the largest AUC for ES PDFF at the L4/5 level (AUC = 0.646, cut-off value = 47.5), while males have lower PDFF compared to females. BMI has a positive impact on the ES PDFF only at the L4/5 level (AUC = 0.559, cut-off value = 24.535).
CONCLUSION: The degree of paraspinal muscles fat infiltration in CLBP patients is related to the cumulative or synergistic effects of multiple factors, especially at the L4/L5 level. Although age and BMI are important factors affecting the degree of paraspinal muscles PDFF in CLBP patients, their diagnostic efficacy is moderate.
The invention relates to Tiandi life-prolonging pills. The Tiandi life-prolonging pills comprise the following raw materials: asparagus tuber, polygonatum rhizome, glutinous rehmannia, turpentine, and wheat bran. The medicine has the functions of dispelling chills and fever, quenching thirst, moisturizing dryness and nourishing yin, supplementing center and boosting qi, benefiting stomach, dispelling wind-damp, engendering flesh and relieving pain, expelling pus and exhaust qi, moistening heart-lung, treating weakness and sickness, expelling blood-arthralgia, regenerating muscle, promoting marrow generation, preventing miscarriages, dispelling various diseases, and prolonging life after long-term administration. The medicine is mainly used for treating emphysema, pulmonary abscess, liver abscess, acute respiratory syndrome, cough and asthma relieving, and vomiting of pregnancy. An administration method and a usage amount are characterized in that the medicine is administrated by three times every day, and 3 g of the medicine is taken each time with warm water before dinner. Side effects of the drug are still not clear. Contraindication is still not clear. The effect is characterized in that after an emphysema patient takes the medicine for 2-3 days, symptom is obviously alleviated, and body is obviously improved by continuous administration for 10 days, the emphysema patient can be cured by continuous administration for 3 months, and the emphysema patient with long-term disease course can be cured by continuous administration for 4 months.
Finely divided particles (100-1000, pref. 250-500 microns) are based on di- or tri-esters of glycerol or diesters of ethyleneglycol and a 12-22C saturated fatty acid. Particles prepd. by cooling the liq ester, are used in toothpaste both as agents to give a speckled pleasing appearance and as polishing agents. Compsn. is easily prepd. and innocuous not only orally but when ingested.
Patients will be included after signing informed consent and randomized in either a standard dose arm or a concentration based arm based on prior Ctrough measurements. In the concentration based arm, dosing frequency will be lowered to once every 3 weeks. If patients still have supratherapeutic Ctroughs of adalimumab, these patients will continue adalimumab self-administration every 4 weeks. In the standard based arm, patients will continue on standard dosing schedule. During each study visit blood will be taken in order to quantify Ctroughs. In addition, Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA) score will be evaluated by a physician. Patients complete the Dermatology Life Quality Index (DLQI) and European quality of life EQ-5D instrument at each visit. In addition, in a subset of patients in each treatment arm, additional sampling will be collected by dried blood spot sampling in order to build a PK(PD) model for adalimumab.
Although many psychometric models have been developed on emotions, affect measurements, which represent the measurement of behavioural, subjective and neuropsychophysiological changes associated with an emotional episode, still remains one of the most debated topics. Emotions are entities with blurred boundaries and with substantial idiosyncrasies that characterize their measurable manifestations. One of the most consolidated theoretical reference models for measuring affect is that of James Russel called the "Affective Core Model". According to this model, emotion arises when the undifferentiated and pre-reflective magma of affect (core affect) is attracted by an external (or internal) object that can be defined as emotigenic, i.e. capable of defining the nature of emotional experience by orienting it along two dimensions principal factors. The most used theoretical model for affect measurement is the one that describes an emotional episode in the light of two distinguishable continuous dimensions: that of hedonic value (identifies the degree of pleasantness of the emotional event), of a subjective nature, and that of arousal or psychophysiological activation. Although this model has been widely corroborated in various disciplines, there is still a lack of a clear description of the process that allows an individual to transition from one emotionally object-oriented state to another.

This project proposes and intends to validate a new modality of three-dimensional psychometric modeling of emotions, based on the intersection between the consolidated two-dimensional model of arousal-valence and a third purely cognitive component definable as mental flexibility, capable of including high-level cognitive processes, intrinsically connected with the emotional sphere, such as emotional intelligence (Emotional Intelligence, EI) and emotional regulation.
Respiratory infections have a significant impact in terms of morbidity and mortality, both in the EU and globally and were responsible for the majority of pandemics in the last centuries. Human breath is an attractive sample type, given the ease of sample collection via non-invasive methods, its direct link to the route of transmission, and its potential role as an indicator of infectiousness. In particular, recent studies have focused on the exhaled breath aerosols (XBAs). Aerosol transmission was demonstrated for many respiratory infections, including pandemic influenza, respiratory syncytial virus (RSV), tuberculosis (TB) and COVID-19. Pathogen detection in XBA samples has shown a good sensitivity, but currently available research tools are highly technical and resource demanding. New and simplified XBA collection devices (Face masks, AveloCollect Blow tube device) are currently under evaluation, and further clinical studies are needed in order to assess their feasibility for pathogen detection in clinical practice, especially for etiological diagnosis in patients with unspecific respiratory symptoms.

The objective of this study is to evaluate the feasibility of XBAs collection and analysis (index test) using the molecular tests currently in use at San Raffaele Hospital for the detection of respiratory pathogens in clinical samples, compared to upper respiratory secretion and sputum samples, that will be collected using standard procedures and analysed using the same kits (comparator tests).
The present disclosure relates to the use of an agent for treating an individual afflicted with an inflammatory condition or disease; the agent comprising one or more members of a group consisting of: (i) a polyoxyl hydrogenated castor oil; (ii) a reaction product of ethylene oxide with hydrogenated castor oil; (iii) one or more of a glycerol polyethylene glycol oxystearate and a fatty acid glycerol polyglycol ester, combined with one or more of a polyethylene glycol and glycerol ethoxylate; (iv) one or combination of plant-derived medium chain triglycerides. The agent may be used in conjugation with an anti-inflammatory drug, such as methotrexate, with an A3 adenosine receptor agonist and/or with folic acid. The inflammatory condition or disease is preferably an autoimmune disease. The present disclosure also concerns pharmaceutical compositions comprising the agent as well as methods for treatment of an inflammatory condition or disease. One agent in the context of the present disclosure may be Cremophor, e.g. Cremophor RH40, which may be used in combination with the anti-inflammatory agent, methotrexate (MTX).
All randomized patients will receive Olaparib 200 mg BD +adavosertib 150 mg BD. Following the discontinuation of adavosertib+olaparib treatment arm on 18 April 2019, patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd).
NEW MATERIAL:A thiazolidine derivative shown by the formulaI(the ring A is a cyclohexane ring comprising any methylene ring which constitutes the ring and contains an oxo group or hydroxyl group as a substituent group; R is H or lower alkyl). EXAMPLE:5-[4-C-4- Hydroxy -1- methyl -r-1- cyclohexylmethoxy)benzyl]thiazolidine-2,4-dione. USE:Having lowering action on lipid in the blood and saccharide, useful for remedying human hyperlipemia, diabetes and their complicating diseases. Oral or parenteral medication. PROCESS:A compound shown by the formula II (X is halogen; Z is hydroxyl group or lower alkoxy) is reacted with thiourea preferably in a solvent, to give a compound shown by the formula III, which is hydrolyzed to give a compound shown by the formulaI. The hydrolysis is carried out preferably in a proper solvent in the presence of water and a mineral acid under heating.
PROBLEM TO BE SOLVED: To obtain a reducing agent for adverse effects having an inflammatory inhibiting activity in an alimentary canal induced by administration of an antitumor agent and useful for continuation, etc., of cancer chemotherapy by including chloroiminopyrrolidinylmethylpyrimidinedione as an active ingredient. SOLUTION: This agent is obtained by including 15-chloro-6-(2- iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione represented by the formula as an active ingredient and the resultant agent is capable of reducing adverse effects due to an antitumor agent, e.g. nausea or emesis. For example, 5- fluorouracil, 5-trifluoromethyl-2'-deoxyuridine, irinotecane hydrochloride or cisplatin is cited as the aantitumor agent to be an object of the agent for reducing the adverse effects. The daily dose of the active ingredient of the agent for reducing the adverse effects is preferably about 0.01-100 mg/kg. When the antitumor agent is previously formulated, the daily dose of the antitumor agent is preferably about 0.01-100 mg/kg.
The maintenance dosage of haloperidol decanoate must be individualized with titration upward or downward based on therapeutic response. The usual maintenance range is 10 to 15 times the previous daily dose in oral haloperidol equivalents dependent on the clinical response of the patient.

Close clinical supervision is required during initiation and stabilization of haloperidol decanoate therapy. Haloperidol decanoate is usually administered monthly or every 4 weeks. However, variation in patient response may dictate a need for adjustment of the dosing interval as well as the dose (see CLINICAL PHARMACOLOGY). 

Clinical experience with haloperidol decanoate at doses greater than 450 mg per month has been limited.
A surgical device for clipping tissue is disclosed. The surgical device comprises a housing, a shaft defining a shaft axis, and an end effector. The end effector comprises a first jaw, a second jaw, and a receiver. The first jaw and the second jaw are movable relative to each other between an open position and a closed position. The receiver is at least partially defined between said first jaw and said second jaw. The surgical device further comprises a rotatable clip magazine configured to rotate about the shaft axis, a first advancing system, and a second advancing system. The clip magazine is configured to store at least two clips. The second advancing system is configured to operate sequentially with the first advancing system. The first advancing system and the second advancing system are configured to sequentially advance the clips into the receiver of the end effector.